Cours Antisense Therapeutics Limited Other OTC
Actions
ATHJF
AU000000ANP4
Recherche biotechnologique et médicale
CA 2024 * | 3,6 M 2,39 M 2,16 M | CA 2025 * | 5,3 M 3,53 M 3,18 M | Capitalisation | 73,03 M 48,58 M 43,78 M |
---|---|---|---|---|---|
Résultat net 2024 * | -17 M -11,31 M -10,19 M | Résultat net 2025 * | -31 M -20,62 M -18,58 M | VE / CA 2024 * | 17,8 x |
Trésorerie nette 2024 * | 8,92 M 5,93 M 5,35 M | Trésorerie nette 2025 * | 17,43 M 11,59 M 10,45 M | VE / CA 2025 * | 10,5 x |
PER 2024 * |
-5,17
x | PER 2025 * |
-2,06
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 83,66% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 08/05/23 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 09/11/06 |
Anthony Filippis
COO | Chief Operating Officer | - | 01/11/22 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 09/11/06 |
Ben Price
BRD | Director/Board Member | 68 | 04/10/21 |
James Garner
CEO | Chief Executive Officer | - | 08/05/23 |
Varia. 1 janv. | Capi. | |
---|---|---|
+11,91% | 118 Md | |
+11,60% | 106 Md | |
-4,68% | 24,28 Md | |
-0,82% | 21,96 Md | |
-10,12% | 18,16 Md | |
-42,12% | 16,37 Md | |
-17,47% | 15,56 Md | |
+2,77% | 13,63 Md | |
+34,58% | 12,27 Md |